Results 71 to 80 of about 3,591 (213)
Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. [PDF]
, 2015 Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing.
Albertson, Timothy E +3 more
core +1 more source
Journal of Evidence-Based Medicine, Volume 18, Issue 2, June 2025.ABSTRACT Aim Chronic Obstructive Pulmonary Disease (COPD) is a common chronic airway disease that can lead to decreased lung function in patients. It places a heavy economic burden on patients and society. Traditional Chinese medicine (TCM) and Western medicine have played important roles in managing COPD.
Di Wu +17 more
wiley +1 more source
Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD [PDF]
, 2017 Background: Beta-blockers remain underused in patients with COPD and cardiovascular disease. Aim: We compared how different inhaled therapies affect tolerability of bisoprolol and carvedilol in moderate to severe COPD.
Anderson, W. +5 more
core +2 more sources
The Clinical Respiratory Journal, Volume 19, Issue 5, May 2025.High‐dose, but not medium‐ and low‐dose, ICS use in COPD is associated with risks of osteoporosis or fractures. ABSTRACT Background Inhaled corticosteroid (ICS) is a major pharmacotherapy for chronic obstructive pulmonary disease (COPD), which is associated with various adverse effects.
Wang Chun Kwok +6 more
wiley +1 more source
International Journal of COPD, 2017 Santosh Dhungana, Gerard J Criner Department of Thoracic Medicine and Surgery, Temple Lung Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA Abstract: Long-acting bronchodilators are the mainstay of the treatment of COPD.
Dhungana S, Criner GJ
doaj
Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
International Journal of COPD, 2020 Donald P Tashkin Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USACorrespondence: Donald P TashkinDavid Geffen School of Medicine at UCLA, 10388 Le Conte Avenue, Los Angeles, CA 90095, USATel +1 310 825 3163Fax +1 310 ...
Tashkin DP
doaj
Evaluation of the anti-inflammatory effects of β-adrenoceptor agonists on human lung macrophages [PDF]
, 2016 The principal mechanism by which bronchodilator β-adrenoceptor agonists act is to relax airways smooth muscle although they may also be anti-inflammatory. However, the extent of anti-inflammatory activity and the cell types affected by these agonists are
Gill, S.K. +3 more
core +1 more source
Multicomponent Interventions for Adults With Cancer Cachexia: A Systematic Review
Journal of Cachexia, Sarcopenia and Muscle, Volume 16, Issue 2, April 2025.ABSTRACT Background Cancer cachexia has substantial impacts on people's quality of life. There is no current gold standard treatment, but the complex pathophysiology of cachexia suggests that a multitargeted and individualised treatment approach is needed.
Megan Bowers +6 more
wiley +1 more source
Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD:a network meta-analysis [PDF]
, 2015 BackgroundThe place of long-acting β agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations in stable patients with COPD is not well defined.
Dias, Sofia, Oba, Yuji, Sarva, Siva T
core +2 more sources
Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.Background The advent of single‐inhaler triple therapies (SITTs), including fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), has expanded treatment options for chronic obstructive pulmonary disease (COPD).
Baiquan Zhang +3 more
wiley +1 more source